Secondary_myelodysplastic_syndrome_complicating_therapy_for_osteogenic_sarcoma._A_12-year-old_girl_with_nonmetastatic_osteogenic_sarcoma_received_treatment_with_doxorubicin,_methotrexate,_cisplatin,_cyclophosphamide,_bleomycin,_and_dactinomycin._She_developed_unexplained_persistent_pancytopenia_after_completion_of_chemotherapy._Twenty-three_months_after_the_initial_diagnosis_of_osteosarcoma_an_evaluation_revealed_a_bone_marrow_pattern_consistent_with_the_diagnosis_of_refractory_anemia_with_excess_blasts,_and_karyotype_analysis_showed_characteristic_findings_of_therapy-related_myelodysplasia_(loss_of_chromosomes_5_and_7,_as_well_as_12p_and_17p_deletions)._Bone_marrow_transplantation_from_an_human_leukocyte_antigen_(HLA)-compatible_sibling_donor_was_performed_26_months_after_the_diagnosis_of_the_primary_malignancy._Although_it_is_unproven_that_the_alkylating_agents_administered_to_this_patient_were_responsible_for_the_myelodysplastic_syndrome,_careful_follow-up_of_osteosarcoma_patients_who_receive_alkylating_agents_is_warranted.